Drug interactions
Enzalutamide + Pralsetinib
Severity: Major
Enzalutamide and Pralsetinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Strong CYP3A induction lowers pralsetinib exposure, potentially reducing efficacy in RET-driven cancers.
What this interaction means in plain words
Enzalutamide and Pralsetinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Enzalutamide belongs to Endocrine; Pralsetinib belongs to Oncology.
Why it happens
Enzalutamide induces CYP3A4, increasing pralsetinib clearance.
What to do
Avoid the combination. If necessary, double the pralsetinib dose from day 7 of coadministration and return to the prior dose at least 14 days after stopping the inducer.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Enzalutamide and Pralsetinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Enzalutamide
- Doravirine + Enzalutamide Contraindicated
- Elbasvir / grazoprevir + Enzalutamide Contraindicated
- Ensitrelvir + Enzalutamide Contraindicated
- Enzalutamide + Fostemsavir Contraindicated
- Enzalutamide + Isavuconazonium Contraindicated
- Enzalutamide + Lenacapavir Contraindicated
Other interactions of Pralsetinib
Frequently asked questions
Can I take Enzalutamide with Pralsetinib?
MediHelp rates the interaction as major. Enzalutamide and Pralsetinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Strong CYP3A induction lowers pralsetinib exposure, potentially reducing efficacy in RET-driven cancers.
How serious is the interaction between Enzalutamide and Pralsetinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination. If necessary, double the pralsetinib dose from day 7 of coadministration and return to the prior dose at least 14 days after stopping the inducer.
What other medicines interact with Enzalutamide?
MediHelp also lists interactions of Enzalutamide with, for example, Doravirine, Elbasvir / grazoprevir, Ensitrelvir. The full list is on the Enzalutamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
